On October 07, 2022 InnovoTEX, an Austin-based pharmaceutical company, reported that the company is developing next generation anti-cancer agents that localize to solid tumors and overcome resistance mechanisms with minimal side effects, to overcome the limited efficacy in drug-sensitive and drug-resistant solid tumors of the traditional chemotherapies (Press release, InnovoTEX, OCT 7, 2022, View Source [SID1234637954]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

InnovoTEX is developing its proprietary TEX Core platform, which utilizes the tumor-localizing and well-tolerated small molecule, texaphyrin, as the basis for a series of conjugates designed to target and treat both drug-sensitive and drug-resistant solid tumors.

The first clinical candidate to be commercialized from the platform is OxaliTEX, a novel chemical entity (WO2015/191797) in a pro-drug form. Patent applications covering both composition and methods of treatment claims for OxaliTEX have been filed in 15 global jurisdictions. Currently, OxaliTEX patents covering the core compositions have been issued in the United States, Australia, Israel, South Korea, Mexico and Singapore.

Pre-clinical research conducted at the University of Texas at Austin and MD Anderson Cancer Center has demonstrated oncolytic activity in multiple indications. OxaliTEX was found to completely inhibit the tumor growth in platinum-resistant patient derived xenografts and result in extended survival of ovarian and colon cancer models. Platinum-resistant ovarian cancer is the planned lead indication for OxaliTEX.

"From the preclinical data generated, OxaliTEX has displayed greater efficacy and tolerability against advanced human cancer models compared to traditional chemotherapies. We are optimistic that OxaliTEX’s therapeutic benefits will translate well to the clinic with further development," InnovoTEX CEO, Dr. Jonathan Arambula said.

Professor Jonathan Sessler, R.P. Doherty, Jr. – Welch Regents Chair in Chemistry at the University of Texas at Austin, partnered with Dr. Arambula and Dr. Zahid Siddik at MD Anderson Cancer Center, in developing technologies that led to OxaliTEX.

"I am excited to see this technology moving to the next level of development and advancing to the clinic for the treatment of a disease for which our current therapeutic options are still unsatisfactory," Professor Sessler said.

Research was generously funded by multiple institutions, including the Cancer Prevention and Research Institute of Texas, the National Institutes of Health and the Robert A. Welch Foundation.

On October 7, 2022 BridGene Biosciences, Inc., a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high value, traditionally undruggable targets, reported that two abstracts featuring the application of the company’s proprietary chemoproteomic platform IMTAC and the company’s leading program TEAD inhibitors, have been accepted for poster presentation and discussion sessions at the 34th (ENA 2022) European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI), and American Association for Cancer Research (AACR) (Free AACR Whitepaper) Symposium, which is being held October 26-28, 2022, in Barcelona (Press release, Bridgene Biosciences, OCT 7, 2022, View Source [SID1234621839]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ENA 2022 will feature experts in cancer drug development and translational research who facilitate in-depth scientific discussions on the latest developments in targets and drugs from pre-clinical and phase I settings.

BridGene’s IMTAC enables the screening of small molecules against the whole proteome or selected targets in live cells to discover drug candidates for traditionally undruggable targets that are responsible for destructive diseases, including multiple types of cancer.

"We are delighted to announce that two abstracts have been accepted for presentation at ENA 2022. The abstracts feature research highlighting the capabilities of our IMTAC platform to identify novel therapeutic targets and novel compounds to drug ‘hard to drug’ targets," commented Ping Cao, Ph.D., Co-founder and CEO of BridGene Biosciences. "This symposium is internationally renowned for the quality of ground-breaking data presented. Our research being featured twice reflects the outstanding value of BridGene’s unique technology in drug discovery and development."

On October 7, 2022 At the 37th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting (SITC 2022), set to take place on November 8-12, 2022, in Boston, Massachusetts (United States), via in person/virtual attendance, Antengene reported that it will release data from preclinical studies of four pipeline assets, ATG-031, ATG-101, ATG-018, and ATG-027, in one oral presentation and three poster presentations (Press release, Antengene, OCT 7, 2022, View Source [SID1234621838]). As the world’s largest and most anticipated gathering in the field of immuno-oncology, the SITC (Free SITC Whitepaper) Annual Meeting is designed to promote scientific exchanges and cooperation for improving treatment outcomes for cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 7, 2022 Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, reported that it has obtained a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets (Press release, Replimune, OCT 7, 2022, View Source [SID1234621835]). This non-dilutive capital extends cash runway into 2025 ahead of key catalysts from the Company’s registration-directed CERPASS and IGNYTE trials in cutaneous squamous cell carcinoma (CSCC) and anti-PD1 failed melanoma inclusive of the costs of funding commercial infrastructure and the running of a confirmatory study to support a potential BLA filing in anti-PD1 failed melanoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This non-dilutive financing option provides Replimune with significant flexibility as we prepare for key RP1 skin franchise data catalysts and related commercial preparations of our novel tumor-directed oncolytic immunotherapies as well as the advancement of RP2/3 into Phase 2 studies," said Jean Franchi, Chief Financial Officer of Replimune. "Not only does this non-dilutive financing strengthen what we believe to be an already strong financial position, it creates optionality in future capital formation and enables us to choose when, and to what extent, we access available funding in order to help manage future cost of capital and dilution."

"Hercules strives to align with some of the best and brightest companies in the life sciences industry to provide them with long-term capital commitments to help them achieve their ambitious goals. We are excited to collaborate with Replimune and their team ahead of numerous data, regulatory, and commercial milestones," said Bryan Jadot, Senior Managing Director and Group Head at Hercules Capital.

The loan facility consists of up to six tranches, five of which can be drawn at Replimune’s option and each maturing in October 2027. The loan facility provides for at least 48-months of interest-only at close, which interest-only period can be extended up to 60 months upon satisfaction of certain milestones. An initial $30 million tranche was funded at closing with an additional $30 million available to be drawn at Replimune’s option prior to September 30, 2023. An additional $115 million is available subject to the Company’s achievement of specified performance milestones relating to clinical, regulatory, and commercial events. The final $25 million tranche is available for draw, at Replimune’s option and subject to Hercules consent during the interest-only period.

Armentum Partners acted as the Company’s exclusive financial advisor on this transaction.

On October 7, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported the Company’s participation in the following upcoming investor and industry conferences to be held in October 2022 (Press release, Genprex, OCT 7, 2022, View Source [SID1234621834]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Dawson James Securities Annual Small Cap Growth Conference

Event: Immuno-Oncology Summit

Event: BIO Europe

Event: LD Micro Main Event XV

Live Webcast Link: https://bit.ly/3EgC5af

For those interested in meeting Genprex management at LD Micro’s Main event, please request a meeting through LD Micro or reach out to Kalyn Dabbs at [email protected].